Alere (ALRPRB.PFD) Debt-to-Equity : 1.65 (As of Jun. 2017)

View and export this data going back to 2008. Start your Free Trial

What is Alere Debt-to-Equity?

Alere's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2017 was $86.67 Mil. Alere's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2017 was $2,820.78 Mil. Alere's Total Stockholders Equity for the quarter that ended in Jun. 2017 was $1,760.41 Mil. Alere's debt to equity for the quarter that ended in Jun. 2017 was 1.65.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Alere's Debt-to-Equity or its related term are showing as below:

ALRPRB.PFD' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.59 Med: 0.93 Max: 4.08
Current: 1.65

During the past 13 years, the highest Debt-to-Equity Ratio of Alere was 4.08. The lowest was -7.59. And the median was 0.93.

ALRPRB.PFD's Debt-to-Equity is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 0.22 vs ALRPRB.PFD: 1.65

Alere Debt-to-Equity Historical Data

The historical data trend for Alere's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alere Debt-to-Equity Chart

Alere Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Debt-to-Equity

Get a 7-Day Free Trial

1.70

1.85

1.95

1.48

1.62

Alere Quarterly Data
	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17
Debt-to-Equity	Get a 7-Day Free Trial															1.48	1.45	1.62	1.62	1.65

Competitive Comparison of Alere's Debt-to-Equity

For the Diagnostics & Research subindustry, Alere's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alere's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Alere's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Alere's Debt-to-Equity falls into.

Alere Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Alere's Debt to Equity Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(85.434	+	2865.426)	/	1826.992
	=	1.62

Alere's Debt to Equity Ratio for the quarter that ended in Jun. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(86.671	+	2820.775)	/	1760.41
	=	1.65

Alere (NYSE:ALRPRB.PFD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Alere Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Alere's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Alere (ALRPRB.PFD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Alere Inc (NYSE:ALRPRB.PFD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.alere.com

Alere, Inc. develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.

Executives

John Bridgen	officer: Sr VP, Business Development	51 SAWYER ROAD, C/O INVERNESS MEDICAL INNOVATIONS INC, WALTHAM MA 02453
Geoffrey S Ginsburg	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Renuka Uppaluri	officer: Senior VP, Global R&D	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mark Gladwell	officer: Senior VP, Global Operations	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Gregg J Powers	director	C/O QUANTUM CORPORATION, 224 AIRPORT PARKWAY SUITE 300, SAN JOSE CA 95110
Jonathan Wygant	officer: VP, Controller, CAO	3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Thomas Mckillop	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Melissa Guerdan	officer: SVP, Global Quality & Reg.	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Daniella Cramp	officer: Global Pres., Cardiometabolic	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Sanjay Malkani	officer: Global Pres., Toxicology	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
James Jr. Roosevelt	director	51 SAWYER ROAD, SUITE 200, HOPKINTON MA 02453
Robert Bernard Hargadon	officer: SVP, Global Human Resources	4327 LAKE WASHINGTON BLVD NE #6208, KIRKLAND WA 98033
John F Levy	director	C/O INNVERNESS MEDICAL INNOVATIONS, INC., 51 SAWYER ROAD, WALTHAM MA 02453
John Quelch	director	C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYER RD, WALTHAM MA 02453
Carol R Goldberg	director	C/O INVERNESS MEDICAL INNOVATIONS INC, 51 SAWYERS RD, WALTHAM MA 02453